ABSTRAK Latar belakang: Laringomalasia merupakan kondisi kelemahan struktursupraglotis saat inspirasi sehingga menyebabkan sumbatan jalan nafas atas danmenimbulkan gejala stridor inspirasi. Stridor semakin memburuk pada posisiterlentang. Penyakit penyerta laringomalasia umumnya adalah reflukslaringofaring (RLF) yaitu 25-68%. RLF adalah pergerakan isi lambung secararetrograd menuju laring-faring, menimbulkan gejala dan tanda klinis yangbervariasi. Pemberian omeperazol dapat memperbaiki gejala regurgitasi danstridor serta memperpendek durasi perjalanan alamiah laringomalasiaTujuan: Mengetahui efektifitas omeperazol pada bayi dan anak denganlaringomalasia, mengetahui prevalensi RLF pada laringomalasia, ada tidaknyaRLF berdasar nilai reflux finding score (RFS) menurut Belafsky dan mengetahuiberat ringan gejala laringomalasia berdasar nilai laryngomalacia symptom score(LSS).Metode: Uji controlled trials pada 65 subyek laringomalasia, dibagi kedalamkelompok 42 subyek yang mendapat omeperazol 2 x 2 mg/kg/bb dan 23 subyekyang mendapat plasebo selama 3 bulanHasil : Kelompok omeperazol dengan gejala berat 58,8% mengalami perbaikandibanding kelompok plasebo 66,7% dengan nilai p = 0,716. Kelompokomeperazol dengan RLF positif 58,3% mengalami perbaikan dibandingkelompok plasebo 75% dengan nilai p = 1.0Simpulan : Prevalensi RLF positif sebesar 24,6% dan gejala berat sebesar 44,6%.Efektifitas pemberian omeperazol selama 3 bulan belum terbukti efektif dibandingplasebo berdasarkan perbaikan nilai LSS, RFS dan status gizi. Namun hasiltersebut hanya berlaku sebagai kesimpulan penelitian pendahuluan karena tidakoptimalnya besar sampel dan randomisasi subyek. Perlu penelitian lanjutan untukmembuktikan efektifitas omeperazol pada perbaikan skor LSS, skor RFS danstatus gizi bayi dan anak dengan laringomalasia ABSTRACT Background: laryngomalacia is condition of floopy supraglottis stucture inrespiratory that trigger obstruction the upper airway and it causes symptom stridorinspiratory. Stridor can get worse in face up position. In general, the comorbidityof laryngomalacia is laryngopharyngeal reflux (LPR) about 25-68%. LPR is themovement of gaster retrogradely toward laryngopharyngeal and it triggers varioussymptom and clinical sign. The giving of omeperazole can improve the symptomof regurgitation and stridor and shorten the duration of natural disease oflaryngomalaciaObjective: Knowing the effectivity of giving omeperazole to the babies andchildren with laryngomalacia, knowing the prevalance of LPR to thelaryngomalacia, knowing the positibility of LPR based on the value of refluxfinding score (RFS) according to Belafsky and knowing severity of symptomlaryngomalacia based on the value of laryngomalacia symptom score (LSS).Method: Test on controlled trials on 65 samples with laryngomalacia and isdivided into 42 groups that have been given omeperazole 2x2 mg/kg/bw and 23samples that have been given placebo for 3 monthResult: Omeperazol groups with severe symptom showed the improvement of58,8% compared to placebo groups 66,7% with p = 0.716. Omeperazole groupswith RLF positive showed the improvement of 58,3% compared to placebogroups 75 % with p = 1.0Conclusion: The Prevalence of positive LPR based on RFS is 24,6% and withsevere symptom is 44,6%. The effectivity of giving omeperazole for 3 month hasnot proved effective compared to placebo based on the improvement of valueLSS, RFS and nutrition status. However such result is only valid for theconclusion of initial research because the size of samples were not either optimalor randomized. It is necessary to conduct research continution to prove theeffectivity of giving omeperazole on the improvement of LSS score, RFS scoreand nutrition status of babies and children with laryngomalacia |